<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01031524</url>
  </required_header>
  <id_info>
    <org_study_id>09/04</org_study_id>
    <nct_id>NCT01031524</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Efficacy of Malaria Vaccine PfCS 102</brief_title>
  <acronym>DG002</acronym>
  <official_title>Randomized Double-blind Controlled Phase I/IIa Trial to Assess the Efficacy of Malaria Vaccine PfCS 102 (282-383) to Protect Against Artificial Challenge With P. Falciparum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Tropical &amp; Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Tropical &amp; Public Health Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I/IIa double-blind randomized (adjuvant)-controlled trial. 16 volunteers are randomized
      to receive two doses of either 30 µg of PfCS102 formulated in Montanide ISA 720 (verum) or
      ISA 720 alone (control), 60 days apart. Two weeks after the 2nd immunization, 14 volunteers
      are challenged with bites of 5 infected mosquitoes using the NF54 strain of P. falciparum.
      The main outcome will be the length of time between artificial challenge and development of
      blood stage parasitaemia detected by microscopy performed twice a day.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of time between artificial challenge and development of blood stage parasitaemia detected by microscopy</measure>
    <time_frame>1month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Plasmodium Falciparum Malaria</condition>
  <arm_group>
    <arm_group_label>vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 µg of PfCS102 formulated in Montanide ISA 720</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adjuvant</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Montanide ISA 720</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PfCS102</intervention_name>
    <description>Antigen of the sporozoite protein</description>
    <arm_group_label>vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Montanide ISA 720</intervention_name>
    <description>adjuvant alone</description>
    <arm_group_label>adjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  resident in or near Lausanne;

          -  age &gt;18 and &lt;45 years;

          -  written informed consent;

          -  &gt;10/12 correct responses to the questionnaire of understanding.

        Exclusion Criteria:

          -  history of malaria; possible exposure to malaria within the previous 6 months;

          -  positive serology for PfCS102by ELISA;

          -  history of severe reactions or allergy to mosquito bites, artemether/lumefantrine
             (Riamet®) or vaccines;

          -  pregnant or lactating female;

          -  any confirmed or suspected immunodeficient condition;

          -  seropostivity for HIV;

          -  chronic or active neurological, gastrointestinal, cardio-vascular or respiratory
             disease;

          -  hemoglobinopathies;

          -  history of &gt;2 hospitalisations for invasive bacterial infections;

          -  requirement of any chronic medication;

          -  suspected or known current alcohol or illegal drug abuse (excluding cannabis);

          -  any other significant finding which, in the opinion of the investigator, would
             significantly increase the risk of having an adverse outcome from participating in
             this protocol or of dropping out of the study;

          -  a body mass index &lt; 18kg/m2 or &gt; 32 kg/m2;

          -  evidence of past or present psychiatric condition;

          -  seropositivity for HIV, hepatitis C or B (other than HBs Ab);

          -  10-year risk of coronary heart disease &lt;10%;

          -  any clinically significant deviation from the normal range in biochemistry or
             haematology blood tests or in urine analysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Blaise Genton, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ambulatory Care and Community Medicine; University Hospital</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>December 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2009</study_first_posted>
  <last_update_submitted>December 11, 2009</last_update_submitted>
  <last_update_submitted_qc>December 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Blaise Genton</name_title>
    <organization>Department of Ambulatory care and Community Medicine, University of Lausanne</organization>
  </responsible_party>
  <keyword>Plasmodium falciparum malaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

